IPC분류정보
| 국가/구분 |
United States(US) Patent
등록
|
| 국제특허분류(IPC7판) |
|
| 출원번호 |
US-0599373
(2015-01-16)
|
| 등록번호 |
US-10092609
(2018-10-09)
|
|
발명자
/ 주소 |
- Wieser, James A.
- Bell, James Martin
- Sarnat, Richard L.
|
| 출원인 / 주소 |
|
| 대리인 / 주소 |
|
| 인용정보 |
피인용 횟수 :
0 인용 특허 :
41 |
초록
▼
The invention provides medicinal fungal preparations that have twenty or more times more medicinal potency than corresponding medicinal fungal preparations made by prevailing means in the prior art. In particular the invention provides nutrient-supplemented bioactive cell-ruptured cultures of medici
The invention provides medicinal fungal preparations that have twenty or more times more medicinal potency than corresponding medicinal fungal preparations made by prevailing means in the prior art. In particular the invention provides nutrient-supplemented bioactive cell-ruptured cultures of medicinal fungi for which the post-rupture extraction medium is edible or potable, and has no significant side effects. The invention further provides methods to prepare them, and pharmacological preparations based on whole-culture biomass including the growth medium and metabolites.
대표청구항
▼
1. A process for preparing high-potency fungal medicinal materials comprising the steps of: a) growing organisms from a medicinal fungal species in a culture on a cell-based growth medium, wherein: i) the fungal species is a species that is edible when raw; andii) the cell-based growth medium is edi
1. A process for preparing high-potency fungal medicinal materials comprising the steps of: a) growing organisms from a medicinal fungal species in a culture on a cell-based growth medium, wherein: i) the fungal species is a species that is edible when raw; andii) the cell-based growth medium is edible;b) placing at least a portion from-the fungal organisms and at least a portion from the cell-based growth medium into an extraction medium; thereby forming a biomass processing medium, wherein the extraction medium is edible and or potable; andc) in the biomass processing medium, rupturing substantially all cells of the fungal organisms and the growth medium cells that had been placed therein, thereby forming a medicinal composition, wherein; i) the medicinal composition comprises each of the following: contents from the ruptured fungal organisms, contents from the medicinal composition, and the extraction medium;ii) the medicinal composition is edible and or potable; andiii) enzymes and other proteins from the fungal organisms of step (a) remain largely undenatured throughout each of steps (a), (b), and (c). 2. The process of claim 1 wherein the rupturing is performed by a mixer blade. 3. The process of claim 2 wherein the cells are present in an extraction medium that comprises water and an edible oil while the rupturing is performed by the mixer blade. 4. The process of claim 3 wherein the rupturing is performed in an extraction medium at a temperature that is between 0° C. and 40° C., a pH that is between 4 and 10, inclusive; and the extraction medium is substantially free of denaturing compounds that are not generated by the cells themselves. 5. The process of claim 1 wherein the contents of the ruptured cells are subjected to a high-pressure treatment following the rupturing. 6. A pharmaceutical composition that is made by a process for preparing high-potency fungal medicinal materials; wherein the process comprises the steps of: a) growing organisms from a medicinal fungal species in a culture on a cell-based growth medium, wherein: i) the fungal species is a species that is edible when raw; andii) the cell-based growth medium is edible;b) placing at least a portion from the fungal organisms and at least a portion from the cell-based growth medium into an extraction medium, thereby forming a biomass processing medium, wherein the extraction medium is edible and or potable; andc) in the biomass processing medium, rupturing substantially all cells of the fungal organisms and the growth medium cells that had been placed therein, thereby forming a medicinal composition, wherein: i) the medicinal composition comprises each of the following: contents from the ruptured fungal organisms, contents from the medicinal composition, and the extraction medium;ii) the medicinal composition is edible and or potable; andenzymes and other proteins from the fungal organisms of step (a) remain largely undenatured throughout each of steps (a), (b), and (c). 7. The composition of claim 6 wherein the fungal species is selected from the group consisting of macrofungi, microfungi and single-celled fungi. 8. The composition of claim 6 wherein the fungal species is selected from the group consisting of the following species: Agaricus bisporus; Agaricus blazei; Agrocybe aegerita; Auricularia auricular—judae; Calyptella species; Coprinus comatus; Cordyceps sinensis; Flammulina velutipes; Ganoderma lucidum; Grifolia frondosa; Hericium erinaceus; Inonotus obliquus; Kuehneromyces species; Lentinus edodes; Monascus purpureus; Neolentinus adhaereus; Panus species; Phellinus linteus; Pleuroyus ostreatus; Rhizopus oligosporus; Saccharomyces boulardii; Saccharomyces cerevisiae; Schizophyllum commune; Trametes versicolor; Tremella aurantia; Tremella fuciformis; and Tricholoma mongolicum. 9. The composition of claim 6 wherein the fungal species is selected from the group consisting of the following species: Hericium erinaceus; Ganoderma lucidum; Trametes versicolor; Lentinus edodes; Agaricus bisporus; Agaricus blazei; Flammulina velutipes; Grifola frondosa; and Pleuroyus ostreatus. 10. The composition of claim 6 wherein the edible cell-based growth medium is selected from the group consisting of grains, legumes, tubers, starchy roots, fruits. 11. The composition of claim 6 wherein the edible cell-based growth medium is a grain selected from the group consisting of rye, wheat, corn, rice, oats, millet, barley and triticale. 12. The composition of claim 6 wherein the cells been ruptured by a mixer blade. 13. The composition of claim 12 wherein the extraction medium comprises water and further comprises an edible oil. 14. The composition of claim 12 wherein the extraction medium has been filtered to remove particles that are larger than 40 microns. 15. The composition of claim 12 wherein the composition is free of added denaturing compounds. 16. The composition of claim 12 wherein contents of the ruptured cells have been subjected to a high-pressure treatment following the rupturing. 17. A method of treating a subject, comprising pharmaceutical composition to treat a neurological disorder or cancer, and wherein the pharmaceutical composition is made by a process for preparing high-potency fungal medicinal materials, wherein the process comprises the steps of: a) growing organisms from a medicinal fungal species in a culture on a cell-based growth medium, wherein: i) the fungal species is a species that is edible when raw; andii) the cell-based growth medium is edible;b) placing at least a portion from-the fungal organisms and at least a portion from the cell-based growth medium into an extraction medium, thereby forming a biomass processing medium, wherein the extraction medium is edible and or potable; andc) in the biomass processing medium, rupturing substantially all cells of the fungal organisms and the growth medium cells that had been placed therein, thereby forming a medicinal composition, wherein; i) the medicinal composition comprises each of the following: contents from the ruptured fungal organisms, contents from the medicinal composition, and the extraction medium; andii) the medicinal composition is edible and or potable; andenzymes and other proteins from the fungal organisms of step (a) remain largely undenatured throughout each of steps (a), (b), and (c). 18. The method of claim 17 wherein the fungal species is selected from the group consisting of the following species: Agaricus bisporus; Agaricus blazei; Agrocybe aegerita; Auricularia auricular—judae; Calyptella species; Coprinus comatus; Cordyceps sinensis; Flammulina velutipes; Ganoderma lucidum; Grifolia frondosa; Hericium erinaceus; Inonotus obliquus; Kuehneromyces species; Lentinus edodes; Monascus purpureus; Neolentinus adhaereus; Panus species; Phellinus linteus; Pleuroyus ostreatus; Rhizopus oligosporus; Saccharomyces boulardii; Saccharomyces cerevisiae; Schizophyllum commune; Trametes versicolor; Tremella aurantia; Tremella fuciformis; and Tricholoma mongolicum. 19. The method of claim 17 wherein the subject has an affliction that is selected from the group consisting of metastatic cancers. 20. The method of claim 19 wherein the affliction is selected from the group consisting of: Parkinson's Disease, Fahr's Disease, Multiple Sclerosis, and depression.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.